Journal of surgical oncology
-
Negative surgical margins are uncommon for spine sarcomas; hence, adjuvant radiotherapy (RT) may be recommended but tumor dose may be constrained by spinal cord, nerve, and viscera tolerance. ⋯ LC with this treatment is high in patients with primary tumors. Late morbidity appears to be acceptable.
-
Comparative Study
Enhanced recovery in the resection of colorectal liver metastases.
There is limited evidence for the use of enhanced recovery after surgery (ERAS) in patients undergoing hepatectomy, and the impact of the evolution of ERAS over time has not been examined. This study sought to evaluate the effect of an evolving ERAS program in patients undergoing hepatectomy for colorectal liver metastases (CRLM). ⋯ This study suggests that as experience of ERAS evolves, there is a progressive reduction in hospitalization and critical care admission. This is without any increase in morbidity and mortality.
-
Cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemotherapy (HIPEC) treatment of colorectal peritoneal metastases (PM) is an established treatment alternative. The study aim was, first, to investigate the outcome of high-volume disease defined by the peritoneal cancer index (PCI) 20; second, to report the long-term disease-free survival of patients with >5 years observation. ⋯ Treatment of high-volume disease may result in long-term survival and even cure. The key is to reach a complete CRS. The overall cure rate is 22%.
-
Spinal metastasis with epidural encroachment is regarded by several authors to be a contraindication to percutaneous vertebroplasty (PVP) because of the risk of increasing symptomatic leakage of cement. This analysis aims to evaluate the safety and efficacy of PVP in patients with painful spinal metastasis and encroachment of epidural space. ⋯ PVP can be performed safely and effectively in patients with painful spinal metastasis and epidural encroachment.
-
Small lung adenocarcinomas are detected more frequently than in the past. However, the clinicopathologic characteristics and prognostic significance of EGFR/p53 mutations in these tumors remains unclear. ⋯ p53 mutation was significantly correlated with tumor progression, and our findings may provide a rationale for the selective use of adjuvant chemotherapy in stage IB patients with p53 mutations. EGFR mutation was a predictor of EGFR TKI response in relapsed patients.